Reported Earlier, Rhythm Pharmaceuticals Launches IMCIVREE In Japan As First Approved Therapy For Acquired Hypothalamic Obesity, Backed By Phase 3 TRANSCEND Trial Showing 18.8% Placebo-Adjusted BMI Reduction

Loading news article.

Reported Earlier, Rhythm Pharmaceuticals Launches IMCIVREE In Japan As First Approved Therapy For Acquired Hypothalamic Obesity, Backed By Phase 3 TRANSCEND Trial Showing 18.8% Placebo-Adjusted BMI Reduction | WAPE

Reported Earlier, Rhythm Pharmaceuticals Launches IMCIVREE In Japan As First Approved Therapy For Acquired Hypothalamic Obesity, Backed By Phase 3 TRANSCEND Trial Showing 18.8% Placebo-Adjusted BMI Reduction

Article summary

Related companies

Comments —